JP2014523851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523851A5 JP2014523851A5 JP2013546480A JP2013546480A JP2014523851A5 JP 2014523851 A5 JP2014523851 A5 JP 2014523851A5 JP 2013546480 A JP2013546480 A JP 2013546480A JP 2013546480 A JP2013546480 A JP 2013546480A JP 2014523851 A5 JP2014523851 A5 JP 2014523851A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- optionally substituted
- ring
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000005843 halogen group Chemical group 0.000 claims 50
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 47
- 125000001424 substituent group Chemical group 0.000 claims 40
- 125000004093 cyano group Chemical group *C#N 0.000 claims 17
- 125000004043 oxo group Chemical group O=* 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 8
- 125000003277 amino group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- -1 pyrrolidyl Chemical group 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 4
- AWEGTPPFDJUPRI-UHFFFAOYSA-N 8-oxabicyclo[3.2.1]octane Chemical group C1CCC2CCC1O2 AWEGTPPFDJUPRI-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical group C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 claims 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
- 150000001924 cycloalkanes Chemical class 0.000 claims 3
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000003566 oxetanyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 150000003527 tetrahydropyrans Chemical group 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 102000003678 AMPA Receptors Human genes 0.000 claims 2
- 108090000078 AMPA Receptors Proteins 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000005936 piperidyl group Chemical group 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 claims 1
- 150000008371 chromenes Chemical class 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- ZQOIMHOVNYHCJG-WBMJQRKESA-N n-[(3r,4s)-3-[[4-(4-chloropyrazol-1-yl)phenoxy]methyl]oxan-4-yl]methanesulfonamide Chemical compound CS(=O)(=O)N[C@H]1CCOC[C@@H]1COC1=CC=C(N2N=CC(Cl)=C2)C=C1 ZQOIMHOVNYHCJG-WBMJQRKESA-N 0.000 claims 1
- KSZRADIOKHDYGB-KUHUBIRLSA-N n-[(3r,4s)-4-[[4-(5-chloro-3-fluoropyridin-2-yl)phenoxy]methyl]oxan-3-yl]cyclopropanesulfonamide Chemical compound FC1=CC(Cl)=CN=C1C(C=C1)=CC=C1OC[C@@H]1[C@@H](NS(=O)(=O)C2CC2)COCC1 KSZRADIOKHDYGB-KUHUBIRLSA-N 0.000 claims 1
- NSBCQSCGEOPIJR-UHFFFAOYSA-N n-[3-[[4-[5-(trifluoromethyl)pyridin-2-yl]phenoxy]methyl]oxan-4-yl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1CCOCC1COC1=CC=C(C=2N=CC(=CC=2)C(F)(F)F)C=C1 NSBCQSCGEOPIJR-UHFFFAOYSA-N 0.000 claims 1
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940043274 prophylactic drug Drugs 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013546480A JP5976011B2 (ja) | 2011-04-05 | 2012-04-05 | スルホンアミド誘導体およびその用途 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011084100 | 2011-04-05 | ||
| JP2011084100 | 2011-04-05 | ||
| PCT/JP2012/059949 WO2012137982A2 (en) | 2011-04-05 | 2012-04-05 | Sulfonamide derivative and use thereof |
| JP2013546480A JP5976011B2 (ja) | 2011-04-05 | 2012-04-05 | スルホンアミド誘導体およびその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523851A JP2014523851A (ja) | 2014-09-18 |
| JP2014523851A5 true JP2014523851A5 (cg-RX-API-DMAC7.html) | 2015-05-21 |
| JP5976011B2 JP5976011B2 (ja) | 2016-08-23 |
Family
ID=46028103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013546480A Active JP5976011B2 (ja) | 2011-04-05 | 2012-04-05 | スルホンアミド誘導体およびその用途 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9527807B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2694472B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5976011B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012137982A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2813508B1 (en) | 2012-02-08 | 2018-01-31 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
| EP3015458A1 (en) * | 2014-11-03 | 2016-05-04 | Bayer CropScience AG | Process for preparing 3,5-bis(haloalkyl)pyrazole derivatives from a,a-dihaloamines and ketimines |
| EP3122727B1 (en) | 2014-03-24 | 2018-01-31 | Bayer CropScience Aktiengesellschaft | Process for preparing 3,5-bis(haloalkyl)pyrazole derivatives from alpha , alpha-dihaloamines and ketimines |
| PL3984994T3 (pl) * | 2016-02-04 | 2024-11-04 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydyny jako agonista oreksyny typu 2 do leczenia narkolepsji |
| EP3436021A4 (en) * | 2016-03-29 | 2019-11-06 | RespireRx Pharmaceuticals Inc. | COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDER |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| US11059780B2 (en) | 2017-03-08 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| WO2018164192A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| IL300063B2 (en) * | 2017-08-03 | 2024-02-01 | Takeda Pharmaceuticals Co | Methanesulfonamide and its use for the prevention or treatment of narcolepsy |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| ES2971497T3 (es) | 2017-10-06 | 2024-06-05 | Takeda Pharmaceuticals Co | Compuestos heterocíclicos |
| JP7250686B2 (ja) | 2017-10-06 | 2023-04-03 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7301840B2 (ja) | 2017-12-19 | 2023-07-03 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸 |
| TW201927778A (zh) | 2017-12-19 | 2019-07-16 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之環己基酸三唑唑類 |
| US11319309B2 (en) | 2017-12-19 | 2022-05-03 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as LPA antagonists |
| TW202017918A (zh) | 2017-12-19 | 2020-05-16 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之環己基酸三唑吖 |
| US11180488B2 (en) | 2017-12-19 | 2021-11-23 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists |
| CN112521368B (zh) | 2017-12-19 | 2023-12-05 | 百时美施贵宝公司 | 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸 |
| JP7256807B2 (ja) | 2017-12-19 | 2023-04-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール |
| EA039459B1 (ru) * | 2017-12-25 | 2022-01-28 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа |
| KR20200132858A (ko) * | 2018-03-20 | 2020-11-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간질 치료제 |
| WO2020004537A1 (ja) | 2018-06-29 | 2020-01-02 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP7339250B2 (ja) | 2018-06-29 | 2023-09-05 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| ES2948793T3 (es) | 2018-09-18 | 2023-09-19 | Bristol Myers Squibb Co | Acidos cicloheptílicos como antagonistas de LPA |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2020122093A1 (ja) * | 2018-12-12 | 2020-06-18 | 武田薬品工業株式会社 | 複素環化合物 |
| CN118271298A (zh) | 2019-01-31 | 2024-07-02 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| TW202045476A (zh) | 2019-02-13 | 2020-12-16 | 美商默沙東藥廠 | 5-烷基吡咯啶食慾素受體促效劑 |
| EP3923933A4 (en) | 2019-02-13 | 2022-08-17 | Merck Sharp & Dohme Corp. | PYRROLIDINOREXINE RECEPTOR AGONISTS |
| EP3986551B1 (en) | 2019-06-18 | 2025-10-29 | Bristol-Myers Squibb Company | Triazole carboxylic acids as lpa antagonists |
| KR20220024549A (ko) | 2019-06-18 | 2022-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 카르복실산 |
| EP3986553A1 (en) | 2019-06-18 | 2022-04-27 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as lpa antagonists |
| WO2021026047A1 (en) * | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| IL320038A (en) | 2019-11-25 | 2025-06-01 | Alkermes Inc | Substituted macrocyclic compounds compositions comprising same and uses thereof |
| US12448377B2 (en) | 2019-11-27 | 2025-10-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AU2021329805B2 (en) | 2020-08-18 | 2024-02-29 | Merck Sharp & Dohme Llc | Bicycloheptane pyrrolidine orexin receptor agonists |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| JP2025510384A (ja) | 2022-03-28 | 2025-04-14 | バイエル アクチェンゲゼルシャフト | シス－４－アミノテトラヒドロフラン－２－カルボン酸エステルの調製方法 |
| US20250250230A1 (en) | 2022-04-12 | 2025-08-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP2025521503A (ja) * | 2022-06-21 | 2025-07-10 | アルカームス インコーポレーテッド | 置換ピロリジニル及びピペリジニル化合物並びに関連する治療方法 |
| WO2023249873A2 (en) * | 2022-06-21 | 2023-12-28 | Alkermes, Inc. | Substituted fused bicyclic compounds and related methods of treatment |
| JP2025521507A (ja) * | 2022-06-21 | 2025-07-10 | アルカームス インコーポレーテッド | 置換縮合二環式化合物および関連する治療方法 |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| CN115433102B (zh) * | 2022-10-16 | 2024-02-27 | 大连双硼医药化工有限公司 | 一种反式-(1r,2r)-2-氨基环己烷羧酸乙酯盐酸盐的制备方法 |
| CN120322433A (zh) | 2022-10-31 | 2025-07-15 | 武田药品工业株式会社 | 杂环化合物 |
| EP4626546A1 (en) | 2022-11-30 | 2025-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| AR132145A1 (es) | 2023-03-16 | 2025-05-28 | Takeda Pharmaceuticals Co | Compuestos heterocíclicos macrocíclicos y sus usos |
| WO2025111184A1 (en) | 2023-11-21 | 2025-05-30 | Fmc Corporation | Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides |
| WO2025229495A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2025229494A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2765322A (en) | 1953-03-03 | 1956-10-02 | Rohm & Haas | Preparation of bis(4-glycidyloxyphenyl)-sulfone |
| US5315013A (en) | 1988-01-07 | 1994-05-24 | E. I. Du Pont De Nemours And Company | Substituted pyrazole angiotensin II antagonists |
| KR100338855B1 (ko) | 1996-07-31 | 2002-12-28 | 시오노기세이야쿠가부시키가이샤 | 신규 파라테르페닐 화합물 |
| DE19803396A1 (de) | 1998-01-29 | 1999-08-05 | Bayer Ag | Substituierte Phenyluracile |
| CA2332452C (en) | 1998-05-20 | 2009-09-08 | Osaka Gas Company Limited | Nonaqueous secondary cell and method for controlling the same |
| CN1245380C (zh) * | 1998-07-24 | 2006-03-15 | 帝人株式会社 | 邻氨基苯甲酸衍生物 |
| CN1391473A (zh) * | 1999-06-30 | 2003-01-15 | 第一制药株式会社 | Vla－4抑制剂化合物 |
| EP1489077A4 (en) | 2002-02-01 | 2006-06-21 | Dainippon Sumitomo Pharma Co | 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
| JP2003238538A (ja) | 2002-02-12 | 2003-08-27 | Nippon Nohyaku Co Ltd | 新規４−置換フェニル−５−ハロピリミジン誘導体及びこれを有効成分とする除草剤 |
| JP2005060385A (ja) | 2003-07-31 | 2005-03-10 | Dainippon Pharmaceut Co Ltd | ２−フランカルボン酸ヒドラジド化合物からなる医薬 |
| WO2006015827A1 (en) | 2004-08-09 | 2006-02-16 | Glaxo Group Limited | Compounds which potentiate glutamate receptor and uses thereof in medicine |
| GB0417709D0 (en) | 2004-08-09 | 2004-09-08 | Glaxo Group Ltd | Compounds |
| DE602005015119D1 (de) | 2004-08-09 | 2009-08-06 | Glaxo Group Ltd | Verbindungen, die den glutamatrezeptor verstärken und anwendungen davon in der medizin |
| JPWO2006088246A1 (ja) | 2005-02-18 | 2008-07-10 | 武田薬品工業株式会社 | Ｇｐｒ３４受容体機能調節剤 |
| UA92007C2 (ru) | 2005-05-04 | 2010-09-27 | Н.В. Органон | Производные 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолина для лечения бесплодности |
| DE602006003661D1 (de) | 2005-06-06 | 2008-12-24 | Lilly Co Eli | Ampa-rezeptoren-verstärker |
| US7956220B2 (en) | 2005-07-01 | 2011-06-07 | Jenrin Discovery | MAO-B inhibitors useful for treating obesity |
| JP5014334B2 (ja) * | 2005-10-06 | 2012-08-29 | イーライ リリー アンド カンパニー | Ａｍｐａ受容体増強剤 |
| GB0602560D0 (en) | 2006-02-08 | 2006-03-22 | Glaxo Group Ltd | Compounds |
| EP1981865A1 (en) | 2006-02-08 | 2008-10-22 | Glaxo Group Limited | 4-phenyl-3-(2-propylsulfonylamino) tetrahydrofuran derivatives which potentiate glutamate receptors and are useful in the treatment of schizophrenia |
| EA015600B1 (ru) | 2006-12-11 | 2011-10-31 | Эли Лилли Энд Компани | Агенты, усиливающие действие амра-рецепторов |
| WO2008113795A1 (en) | 2007-03-20 | 2008-09-25 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| JP2010523540A (ja) | 2007-04-03 | 2010-07-15 | ファイザー・インク | スルホンアミドおよびその医薬組成物 |
| US8173820B2 (en) | 2007-12-19 | 2012-05-08 | Glaxo Group Limited | Compounds which potentiate the AMPA receptor and uses thereof in medicine |
| GB0801265D0 (en) | 2008-01-23 | 2008-02-27 | Glaxo Group Ltd | Compounds |
| GB0801220D0 (en) | 2008-01-23 | 2008-02-27 | Glaxo Group Ltd | Compounds |
| CA2718727A1 (en) | 2008-03-25 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| TW201012803A (en) * | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| EP2356099A1 (en) | 2008-10-08 | 2011-08-17 | Pfizer Inc. | Tetrahydrofuranyl sulfonamides for use as ampa modulators in the treatment of cns disorders |
| AU2010233694A1 (en) | 2009-04-09 | 2011-09-29 | Merck Sharp & Dohme B.V. | Indane derivatives |
| SI2445883T1 (sl) | 2009-06-26 | 2014-10-30 | Pfizer Inc. | Heterociklični sulfonamidi, uporabe in njihovi farmacevtski sestavki |
| KR20120052341A (ko) | 2009-07-23 | 2012-05-23 | 노파르티스 아게 | 신경 세로이드 리포푸스신증의 치료에 사용하기 위한 1ｈ-퀴나졸린-2,4-디온 |
| JP5788496B2 (ja) | 2010-08-10 | 2015-09-30 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
-
2012
- 2012-04-05 EP EP12719088.2A patent/EP2694472B1/en active Active
- 2012-04-05 WO PCT/JP2012/059949 patent/WO2012137982A2/en not_active Ceased
- 2012-04-05 US US14/009,456 patent/US9527807B2/en active Active
- 2012-04-05 JP JP2013546480A patent/JP5976011B2/ja active Active